P&G exec tips industrial biotech will dominate
27 February, 2006 by Iain ScottIndustrial biotech will eclipse its so-called 'red' and 'green' cousins, as industries are forced to adapt to environmental pressure, the head of global biosciences at the giant Proctor & Gamble corporation has predicted.
GTG forms alliance with US MetaMorphix
27 February, 2006 by Helen SchullerMelbourne's Genetic Technologies (ASX:GTX, Nasdaq:GENE) has formed a strategic alliance with MetaMorphix, a developer of new genetic markers.
In brief: GTG, Life Therapeutics, AusBiotech, CyGenics
21 February, 2006 by Ruth BeranGenetic Technologies (ASX:GTG; Nasdaq:GENE) has appointed London-based lawyer SJ Berwin to help the company expand its licensing program for its non-coding patents in the UK and in Europe
CSIRO signs research agreement with Chinese Ministry of Science
16 February, 2006 by Helen SchullerThe CSIRO and the Chinese Government have signed an agreement designed to strengthen the relationship between research laboratories in Australia and China.
Panbio subsidiary wins US defence department grant
16 February, 2006 by Ruth BeranPanbio's (ASX:PBO) US subsidiary Panbio Inc has been awarded almost US$100,000 (AUD$135,000) in funding from the US Deparment of Defence.
NSW, China sign tech park agreement
14 February, 2006 by Helen SchullerThe NSW and Chinese governments have signed an agreement to help foster collaborative relationships between science and technology parks and commercial enterprises.
Genmab licenses Bionomics angiogenesis targets
14 February, 2006 by Ruth BeranDanish biotech Genmab has acquired exclusive worldwide rights to angiogenesis targets identified by Adelaide-based Bionomics (ASX:BNO).
Resonance technology gets regulatory support
13 February, 2006 by Helen SchullerAustralian and European authorities have eased the regulatory pathway for Resonance Health (ASX:RHT), by endorsing quality assurance systems for the Perth-based firm's FerriScan technology.
Novartis, Bausch & Lomb to promote pSivida blindness treatment
10 February, 2006 by Helen SchullerPerth-based bio-nanotech company pSivida's (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) Retisert will be co-promoted in the US by Novartis Ophthalmics.
Solagran's liver treatment 'fast tracked' in Russia
10 February, 2006 by Helen SchullerMelbourne-base Solagran has been granted Russian approval to register Ropren, the finished form of Bioeffective R, as a new medicine for the treatment for chronic liver disease.
Biotech Capital reduces stake in C3
10 February, 2006 by Ruth BeranBioTech Capital (ASX:BTC) has reduced its shareholding in Clinical Cell Culture (ASX:CCE, C3) from about 19 per cent to 12 per cent.
In brief: Benitec, Biota, Eqitx
09 February, 2006 by Ruth BeranBenitec (ASX:BLT) has appointed former Axon Instruments VP Michael Catelani as executive director and Boron Molecular founder Peter Francis as non-executive director.
National bioinformatics network gathers speed
09 February, 2006 by Helen SchullerA national bioinformatics network has been established following a $2.2 million grant from the National Health and Medical Research Council of Australia.
Avexa, MNLpharma sign licence agreement
08 February, 2006 by Ruth BeranAvexa (ASX:AVX) has signed an exclusive licence agreement allowing the Melbourne-based company to develop and commercialise a number of HIV integrase inhibitors discovered from UK-based MNLpharma's Phytopure library.
Biotech stocks fall in January
08 February, 2006 by Ruth BeranBiotechnology stocks have continued to underperform in January -- with the Intersuisse biotechnology index sliding by 0.9 per cent.
